These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6883348)

  • 1. Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.
    Coleman CN; Friedman MK; Jacobs C; Halsey J; Ignoffo R; Leibel S; Hirst VK; Gribble M; Carter SK; Phillips TL
    Cancer Res; 1983 Oct; 43(10):5022-5. PubMed ID: 6883348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole.
    Coleman CN; Carlson RW; Artim RA; Sampson WI; Lawrence HJ; Wong P; Halsey J; Kohler M; Gribble M; Sikic BI
    Cancer Res; 1988 Jun; 48(12):3528-32. PubMed ID: 2836059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of misonidazole in the United States.
    Wasserman TH; Stetz J; Phillips TL
    Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-dose relationships for simultaneous misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea exposures in vitro.
    Mulcahy RT; Dembs N
    Cancer Res; 1983 Aug; 43(8):3539-43. PubMed ID: 6861127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo interaction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice.
    Siemann DW; Maddison K; Wolf K; Hill SA; Keng PC
    Cancer Res; 1985 Jan; 45(1):198-202. PubMed ID: 3965132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical trials of hypoxic cell sensitizer misonidazole].
    Onoyama Y
    Gan No Rinsho; 1983 May; 29(6):718-25. PubMed ID: 6348345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
    Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
    Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
    Mulcahy RT; Siemann DW
    Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
    Siemann DW; Morrissey S; Wolf K
    Cancer Res; 1983 Mar; 43(3):1010-3. PubMed ID: 6825075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of 5-fluorouracil with misonidazole in patients with advanced colorectal cancer.
    Spooner D; Bugden RD; Peckham MJ; Wist EA
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):387-9. PubMed ID: 7107357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.
    Phillips GL; Meisenberg B; Reece DE; Adams VR; Badros A; Brunner J; Fenton R; Filicko J; Grosso D; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Nath R; Reed E; Rapoport AP; Takebe N; Vesole DH; Wagner JL; Flomenberg N
    Biol Blood Marrow Transplant; 2004 Jul; 10(7):473-83. PubMed ID: 15205668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary results of RTOG phase I/II study of misonidazole and radiation for bladder cancer.
    Mohiuddin M; Kramer S; Phillips T; Soberon M; Forgione H
    Am J Clin Oncol; 1982 Oct; 5(5):551-4. PubMed ID: 7180834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New side effect of the hypoxic cell sensitizer, misonidazole.
    Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
    Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
    Horsman MR; Evans JW; Brown JM
    Br J Cancer; 1984 Sep; 50(3):305-16. PubMed ID: 6466544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.